NCT04846842View on ClinicalTrials.gov

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2023

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

Gimatecan

Patients will receive gimatecan orally at the fixed dose level on day 1-5 every 4 weeks.

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY